**Organisation name: Intensive Care Society**

**Disclosure:** Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry:

**Name of person completing form: xxxxxxxxxxxxx**

|  |  |  |  |
| --- | --- | --- | --- |
| **Comment no.** | **Page** **no.** | **Section no.** | **Comment** Insert each comment in a new row.Do not paste other tables into this table, because your comments could get lost – type directly into this table. |
| 1 | 15 | 1.1 | Carbapenem resistance is a particular problem in Gram-negative bacteria, since this constitutes the most reliable drug class for treating gram negative bacterial infections.  |
| 2 | 15 | 1.1 | Should the examples of carbapenems be limited to meropemen, ertapenem and imipenem with cilastatin. This would be consistent with the summary of carbapenems in the BNF |
| 3 | 19 | 3.1 | followed by a potential extension to 10 years should the be followed by a potential extension of up to 10 years  |
| 4 | 69 | 4.6.2 | Safety implications appear to be covered well given the respective paucity in direct comparison of comparators in the specific context of treatment in HVCSs |
| 5 |  |  |  |
| 6 |  |  |  |
| 7 |  |  |  |
| 8 |  |  |  |

**Insert extra rows as needed**

**Checklist for submitting comments**

* Use this comments form and submit it as a Word document (not a PDF).
* Complete the disclosure about links with, or funding from, the tobacco industry.
* Combine all comments from your organisation into 1 response. We cannot accept more than 1 set of comments from each organisation.
* Do not paste other tables into this table – type directly into the table.
* Please underline all confidential information, and separately highlight information that is submitted under ‘commercial in confidence’ in turquoise and all information submitted under ‘academic in confidence’ in yellow. If confidential information is submitted, please also send a 2nd version of your comment with that information replaced with the following text: ‘academic / commercial in confidence information removed’.
* Do not include medical information about yourself or another person from which you or the person could be identified.
* Do not use abbreviations
* Do not include attachments such as research articles, letters or leaflets. For copyright reasons, we will have to return comments forms that have attachments without reading them. You can resubmit your comments form without attachments, it must be sent by the deadline.

**Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory committees.